QURE uniQure N.V.

uniQure (NasdaqGS:QURE) is back in focus after new 36- and 48-month data for its Huntington’s gene therapy, AMT-130, sparked sharp swings in the share price and renewed debate about the program. uniQure’s share price has been hit hard in the wake of the mixed AMT-130 update, with a 7-day share price return down 36.95% and a 30-day move down 49.52%, even though the year-to-date share price return is still up 3.29% and the 3-year total shareholder return is very large at roughly 2.6x. This...

uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside. Whether that gap represents opportunity or denial depends on one number that cuts both ways.

uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years.

Uniqure stock plummeted Tuesday on a disappointing four-year update for its experimental gene therapy in patients with Huntington's disease.

uniQure (NASDAQ:QURE) reported updated Phase I/II data for its investigational Huntington’s disease gene therapy, ifezuntirgene inilparvovec, or AMT-130, including 36-month results from all high-dose patients and 48-month results from the first 12 high-dose patients to reach that milestone. The com

uniQure N.V. (NASDAQ:QURE) stock is trading lower on Tuesday after the company shared mixed long-term data from ongoing Phase 1/2 clinical studies evaluating ifezuntirgene inilparvovec for Huntington’s disease. 36-Month Clinical Results And BLA Pathway In the 36-month analysis, high-dose patients demonstrated an 80% slowing of disease progression on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) and a 67% slowing on Total Functional Capacity (TFC). cUHDRS is a specialized scori

UniQure says it still sees a path to regulatory approval for the drug candidate, AMT-130, even as the experimental gene therapy for Huntington’s disease falls hort in a recent study.

uniQure N. V. (NASDAQ:QURE) shares fell 64% on Tuesday after the gene therapy developer reported updated 48-month data for ifezuntirgene inilparvovec, or AMT-130, its experimental treatment for Huntington’s disease.

ClearPoint Neuro (NASDAQ:CLPT) shares fell 24% on Tuesday following updated clinical trial results from partner uniQure N. V.

uniQure’s Ifezuntirgene slowed disease progression by 80% on a measure combining movement, thinking and daily function.

Investing.com -- Shares of gene therapy developer uniQure N.V. (NASDAQ: QURE) cratered 64% Tuesday morning following an updated data readout for its experimental Huntington’s disease treatment, ifezuntirgene inilparvovec (AMT-130). While the treatment continued to show a dose-dependent slowing of disease progression, a failure to hit statistical significance on a primary clinical measure at 48 months triggered a massive sell-off.

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

With the Food and Drug Administration’s hard-liners gone, investors are rushing back into rare-disease bets.

uniQure N.V. (NASDAQ:QURE) submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for accelerated approval of ifezuntirgene inilparvovec, formerly AMT-130, in Huntington’s disease. uniQure N.V. (NASDAQ:QURE) also requested priority review, which would provide a six-month review cycle after the FDA completes its 60-day filing review if granted. The application’s clinical-efficacy […]

Price targets for ClearPoint Neuro have shifted toward the low to mid US$20s, with the average assessed fair value moving from US$28.33 to US$23.50 and one outlier still at US$30. Analysts link this change to a period they see as more investment heavy, balancing optimism about long term growth potential with caution around near term execution and partner related contributions. As you read on, you will see how this evolving narrative could shape the way you track ClearPoint Neuro from...

After a very large three year gain in uniQure’s share price, the stock now screens as overvalued on market multiples and carries a mixed overall value score rather than a clear bargain signal. The recent run and the current valuation checks give investors a more finely balanced picture. Over the past three years, uniQure has returned very close to 7x for shareholders, which places extra focus on how much of the company’s future potential is already priced in. The recent Biologics License...

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.

uniQure announced it had submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, or AMT-130, for Huntington’s disease.

Uniqure stock fell Wednesday after asking the Food and Drug Administration to approve its Huntington's gene therapy.

Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.03%, and the actively tr

uniQure (QURE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gene therapy biotech secures FDA alignment for Huntington's disease BLA submission.

uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.

Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls

Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy stocks.

uniQure NV (QURE) reports steady revenue growth and regulatory progress, while navigating high R&D expenses and operational hurdles.

uniQure (NASDAQ:QURE) said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track to submit a biologics license application in the third quarter of 2026. Chief

If approved, uniQure’s AMT-130 would be the first disease-modifying treatment for the inherited neurodegenerative disorder.

uniQure (QURE) delivered earnings and revenue surprises of -50.62% and -17.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

uniQure’s stock has delivered a very large 301.7% return over the past three years. However, on Simply Wall St’s checks it still screens as expensive overall, with a low value score and market multiples that lean toward an overvalued verdict. Over the last three years, uniQure has returned 301.7%, which puts extra focus on whether recent gains leave enough room for mistakes in the story from here. For a research stage biotech like uniQure, future cash needs and the timing of potential...

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.